Cardiovascular molecular imaging of apoptosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 1 SUPPL., 2007, Pages

  Wolters, S L ^a   Corsten, M F ^a   Reutelingsperger, C P M ^a   Narula, J ^b   Hofstra, L ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Annexin A5; Apoptosis; Cardiovascular disease; Molecular imaging

Indexed keywords

5 PYRROLIDINYLSULPHONYL ISATIN; FLUORODEOXYGLUCOSE F 18; LIPOCORTIN 5; PHOSPHATIDYLSERINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; HEART GRAFT; HEART INFARCTION; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

APOPTOSIS; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; HEART; HUMANS; MOLECULAR PROBE TECHNIQUES; MYOCARDIUM;

EID: 34250763665     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0443-0     Document Type: Review

References (93)

1. Narula J, Baliga R. What's in a name? Would that which we call death by any other name be less tragic? Ann Thorac Surg 2001;72(5):1454-6.
2. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins pathologic basis of disease, 6th ed. Philadelphia: W.B. Saunders, 1999.p 1424, xv.
3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26(4):239-57.
4. Leist M, Jaättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2(8):589-98.
5. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3(2):117-29.
6. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4(8):592-603.
7. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5(3):231-7.
8. Castedo M, Perfettini JL, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23(16):2825-37.
9. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290 5497:1717-21.
10. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004;23(16):2891-906.
11. Edinger AL, Thompson CB. Defective autophagy leads to cancer. Cancer Cell 2003;4(6):422-4.
12. Kunapuli S, Rosanio S, Schwarz ER. How do cardiomyocytes die? Apoptosis and autophagic cell death in cardiac myocytes. J Card Fail 2006;12 5:381-91.
13. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002;31(4):214-23.
14. Kroemer G, El-Deiry WS, Golstein P, et al. Classification of cell death: recommendations of the Nomenclature Committee on cell death. Cell Death Differ 2005;12 Suppl 2:1463-7.
15. Scarabelli TM, Knight R, Stephanou A, et al. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol 2006;31(3):181-264.
16. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 2004;13(8):1979-87.
17. Stefflova K, Chen J, Li H, et al. Targeted photodynamic therapy agent with a built-in apoptosis sensor for in vivo near-infrared imaging of tumor apoptosis triggered by its photosensitization in situ. Mol Imaging 2006;5(4):520-32.
18. Bhojani MS, Hamstra DA, Chang DC, et al. Imaging of proteolytic activity using a conditional cell surface receptor. Mol Imaging 2006;5(2):129-37.
19. Darzynkiewicz Z, Bedner E, Smolewski P, et al. Detection of caspases activation in situ by fluorochrome-labeled inhibitors of caspases (FLICA). Methods Mol Biol 2002;203:289-99.
20. Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine- specific clearance of apoptotic cells. Nature 2000;405(6782):85-90.
21. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89(4):1121-32.
22. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182(5):1545-56.
23. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 1998;95(11):6349-54.
24. Dumont EA, Hofstra L, van Heerde WL, et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation 2000;102(13):1564-8.
25. Dumont EA, Reutelingsperger CP, Smits JF, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 2001;7(12):1352-5.
26. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356(9225):209-12.
27. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995;182(5):1597-601.
28. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994;123(5):741-8.
29. Koopman G, Reutelingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84(5):1415-20.
30. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82(2):331-71.
31. Moss SE, Morgan RO. The annexins. Genome Biol 2004;5(4):219.
32. Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun 2004;322(4):1166-70.
33. Reutelingsperger CP. Annexins: key regulators of haemostasis, thrombosis, and apoptosis. Thromb Haemost 2001;86(1):413-9.
34. Hayes MJ, Rescher U, Gerke V, et al. Annexin-actin interactions. Traffic 2004;5(8):571-6.
35. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148(7):2207-16.
36. van Engeland M, Kuijpers HJ, Ramaekers FC, et al. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 1997;235(2):421-30.
37. Kenis H, van Genderen H, Bennaghmouch A, et al. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem 2004;279(50):52623-9.
38. Vriens PW, Blankenberg FG, Stoot JH, et al. The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998;116(5):844-53.
39. Post AM, Katsikis PD, Tait JF, et al. Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 2002;43(10):1359-65.
40. Glaser M, Collingridge DR, Aboagye EO, et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 2003;58(1):55-62.
41. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 2004;31(4):469-74.
42. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001;7(12):1347-52.
43. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004;350(14):1472-3.
44. Hofstra L, Dumont EA, Thimister PW, et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA 2001;285(14):1841-2.
45. van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol 2003;21(18):3483-7.
46. 99mTc-annexin A5. Br J Radiol 2003;76(908):553-60.
47. Zhao M, Beauregard DA, Loizou L, et al. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001;7(11):1241-4.
48. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med 2006;47(8):1367-74.
49. Haberkorn U, Kinscherf R, Krammer PH, et al. Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)- fluoromethyl ketone. Nucl Med Biol 2001;28(7):793-8.
50. Kopka K, Faust A, Keul P, et al. 5-Pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J Med Chem 2006;49(23):6704-15.
51. Damianovich M, Ziv I, Heyman SN, et al. ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur J Nucl Med Mol Imaging 2006;33(3):281-91.
52. Aloya R, Shirvan A, Grimberg H, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 2006;11(12):2089-101.
53. Freude B, Masters TN, Kostin S, et al. Cardiomyocyte apoptosis in acute and chronic conditions. Basic Res Cardiol 1998;93(2):85-9.
54. Hiller KH, Waller C, Nahrendorf M, et al. Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol Imaging 2006;5(2):115-21.
55. Sosnovik DE, Schellenberger EA, Nahrendorf M, et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med 2005;54(3):718-24.
56. Libby P. Inflammation in atherosclerosis. Nature 2002;420(6917):868-74.
57. Virmani R, Moll FL, Koekkoek JA, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25(10):2054-61.
58. Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001;16(5):285-92.
59. Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 2000;157(4):1259-68.
60. Narula J, Strauss HW. Imaging of unstable atherosclerotic lesions. Eur J Nucl Med Mol Imaging 2005;32(1):1-5.
61. Clarke MC, Figg N, Maguire JJ, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006;12(9):1075-80.
62. Tsimikas S, Shortal BP, Witztum JL, et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000;20(3):689-97.
63. Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47(8 Suppl):C13-8.
64. Steinberg D, Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997;95(4):1062-71.
65. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis. The importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005;25(11):2255-64.
66. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92(3):657-71.
67. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69(8):729-32.
68. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 1990;66(16):44G-47G.
69. Little WC, Applegate RJ. Role of plaque size and degree of stenosis in acute myocardial infarction. Cardiol Clin 1996;14(2):221-8.
70. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32(2):368-72.
71. Ikeda U, Matsui K, Murakami Y, et al. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 2002;25(4):143-7.
72. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347(20):1557-65.
73. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991;251(4995):788-91.
74. Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res 2000;45(3):736-46.
75. Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 2003;108(25):3134-9.
76. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004;3(11):913-25.
77. Sadeghi MM, Schechner JS, Krassilnikova S, et al. Vascular cell adhesion molecule-1-targeted detection of endothelial activation in human microvasculature. Transplant Proc 2004;36(5):1585-91.
78. Sibson NR, Blamire AM, Bernades-Silva M, et al. MRI detection of early endothelial activation in brain inflammation. Magn Reson Med 2004;51(2):248-52.
79. Ohtsuki K, Hayase M, Akashi K, et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 2001;104(2):203-8.
80. Iuliano L, Mauriello A, Sbarigia E, et al. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: effect of vitamin E supplementation. Circulation 2000;101(11):1249-54.
81. Schafers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004;109(21):2554-9.
82. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105(23):2708-11.
83. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003;108(18):2270-4.
84. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36(7):1301-6.
85. Lederman RJ, Raylman RR, Fisher SJ, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun 2001;22(7):747-53.
86. Vallabhajosula S, Machac K, Knesaurek J. Imaging atherosclerotic macrophage density by positron emission tomography using F-18 flurodeoxyglucose (FDG) [abstract]. J Nucl Med 1996;38P.
87. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med 2005;46(7):1186-93.
88. Strauss HW, Grewal RK, Pandit-Taskar N. Molecular imaging in nuclear cardiology. Semin Nucl Med 2004;34(1):47-55.
89. Wencker D, Chandra M, Nguyen K, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111(10):1497-504.
90. Kietselaer BL, Reutelingsperger CP, Boersma HH, et al. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J Nucl Med 2007; 48(4):562-7.
91. Laguens RP, Meckert PM, Martino JS, et al. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant 1996;15(9):911-8.
92. Szabolcs MJ, Ravalli S, Minanov O, et al. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation 1998;65(6):804-12.
93. Puig M, Ballester M, Matias-Guiu X, et al. Burden of myocardial damage in cardiac allograft rejection: scintigraphic evidence of myocardial injury and histologic evidence of myocyte necrosis and apoptosis. J Nucl Cardiol 2000;7(2):132-9.